Aratana joins biotech IPO queue while Tetraphase takes a haircut

Aratana Therapeutics, which is developing 6 new treatments for cats and dogs, joined the biotech queue on Wall Street, filing an S-1 indicating a desire to raise $57.5 million in an IPO. The company was founded just a few years ago and has since licensed three programs. It's planning to trade shares under  the symbol PETX. In related news, Tetraphase launched its IPO, raising $75 million for its work on antibiotics. The biotech had to slash its price to $7, after offering a range of $10 to $12, and raised the number of shares being sold. Enanta, which is developing hep C drugs, is also expected to go public this week. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.